BUZZ - Acumen shares plunge after mid-stage trial failure for Alzheimer's drug
路透社2026/10/30 13:22Latest Updates
October 30 - ** Acumen Pharmaceuticals (ABOS.O) shares plunged 85% in premarket trading to $0.34
** The biotechnology company said its experimental intravenous drug sabirnetug for Alzheimer's disease failed to meet the primary goal in a mid-stage study, showing no significant effect versus placebo in slowing memory and functional decline
** The company said key secondary measures, including CDR-SB, also failed to reach statistical significance
** While the drug reduced brain amyloid plaque levels, this did not translate to a clinical benefit
** ABOS’s R&D pipeline includes an early-stage subcutaneous formulation of sabirnetug and a preclinical project to enhance brain delivery in collaboration with Japan’s JCR Pharmaceuticals 4552.T
** The company plans to halt development of sabirnetug, discontinue the extension phase of the study, and implement cash preservation measures
** As of the close of the previous trading day, the stock was up about 9% year-to-date
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or lack relevant context, Reuters does not guarantee the accuracy of these automated translations and provides them for readers' convenience only. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Disciplined capital expenditure attracts market favor as Apple (AAPL.US) surpasses Nvidia (NVDA.US) to reclaim the top spot in global market capitalization
As concerns about Wall Street's massive returns on tech giants' artificial intelligence investments continue to intensify, Apple surpassed Nvidia on Friday to once again become the world's most valuable publicly traded company.
AI burning cash sparks credit risk concerns! S&P downgrades Meta (META.US) rating outlook to "negative," questioning its ability to monetize massive investments
S&P Global Ratings has revised Meta's credit rating outlook from “stable” to “negative,” citing the company's continued expansion of artificial intelligence (AI) capital expenditures, which has turned free cash flow negative. There remains uncertainty over whether these significant AI investments will generate sufficient returns in the coming years.
Prospect Ridge Raises $1.84 Million in Private Placement
Crypto prices
More
